

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

ANNOUNCEMENT ON

LEGAL PROCEEDINGS RELATING TO THE COMPANY

This announcement is made by TYK Medicines, Inc (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) to update its shareholders and potential investors on the latest development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces that the Company has recently filed a case with the People's Court of Changxing County (長興縣人民法院) commencing legal proceedings against Sichuan Huiyu Pharmaceutical Co., Ltd.* (四川匯宇製藥股份有限公司, “**Huiyu**”), seeking judicial affirmation that a purported cooperation agreement and distribution agreement with Huiyu pertaining to TY-9591 has not been formed and is invalid.

The Company also received a case filing notice issued by the People's Court of Neijiang City Shizhong District* (內江市市中區人民法院) filed by Huiyu regarding the same cooperation agreement, distribution agreement and related documents purported to have been entered into between the Company and Huiyu. Both cases have been filed but have not yet been heard in court.

The Board has sought and will continue to seek legal advice on the court notices and the accompanying legal proceedings (the “**Legal Proceedings**”) and will continue to assess and monitor their potential legal, operational and financial impact on the Group. Based on the preliminary consultation with the Company's PRC legal adviser, the Board is of the view there are reasonable grounds to contest the formation and validity of the purported cooperation agreement and distribution agreement and support the Company's position, and the Company intends to take all necessary measures to protect its legitimate interest. As at the date of this announcement, so far as the Board is aware: (a) the Legal Proceedings have had no material adverse impact on the overall business, operations or cashflow position of the Group; and (b) the business and operations of the Group remain normal.

The Company will continue to make further announcement(s) on significant progress of the Legal Proceedings as and when appropriate.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, July 22 2026

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director; Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors; and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.

* *English translations of Chinese names are for reference only*